Shots:

• HitGen to receive upfront & milestones and will utilize its DNA-encoded library design technology to develop therapies for Sun Pharma’s SPARC targets
• The focus of the collaboration is to combine the SPARC’s research expertise with HitGen’s DELs based screening technology to develop therapies for serious medical conditions 
• HitGen’s DELs is a platform for small molecule drug discovery including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America- Europe- Asia & Africa to discover therapies & agrochemical solutions

Ref: HitGen | Image: Livemint